Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439152 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT01439152 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 148 participants.
The verdict
NCT01439152, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.
Interventions
- DRUG BAY94-9343
- DRUG BAY94-9343 (Expansion)
- DRUG BAY94-9343 (1.8 mg/kg)
- DRUG BAY94-9343 (2.2 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2011-09-07 |
| Est. Completion | 2019-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439152
The ClinicalTrials.gov registry entry for NCT01439152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BAY94-9343 is the first listed.
NCT01439152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439152 about?
NCT01439152 is a clinical study titled "Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.". BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.
What is the current status of trial NCT01439152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2011-09-07. Estimated completion is 2019-07-30.
What interventions are being tested in trial NCT01439152?
The interventions under investigation include: BAY94-9343 (DRUG), BAY94-9343 (Expansion) (DRUG), BAY94-9343 (1.8 mg/kg) (DRUG), BAY94-9343 (2.2 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT01439152?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.